Annual Revenue
$9.87 B
+$938.50 M+10.51%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual revenue is currently $9.87 billion, with the most recent change of +$938.50 million (+10.51%) on 31 December 2023. During the last 3 years, it has risen by +$3.66 billion (+59.03%). VRTX annual revenue is now at all-time high.VRTX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$2.77 B
+$126.30 M+4.77%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly revenue is currently $2.77 billion, with the most recent change of +$126.30 million (+4.77%) on 30 September 2024. Over the past year, it has increased by +$288.40 million (+11.61%). VRTX quarterly revenue is now at all-time high.VRTX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$10.63 B
+$288.40 M+2.79%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM revenue is currently $10.63 billion, with the most recent change of +$288.40 million (+2.79%) on 30 September 2024. Over the past year, it has increased by +$971.60 million (+10.06%). VRTX TTM revenue is now at all-time high.VRTX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.5% | +11.6% | +10.1% |
| 3 y3 years | +59.0% | +39.7% | +49.0% |
| 5 y5 years | +223.8% | +191.8% | +193.6% |
VRTX Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +59.0% | at high | +39.7% | at high | +49.0% |
| 5 y | 5 years | at high | +223.8% | at high | +191.8% | at high | +193.6% |
| alltime | all time | at high | >+9999.0% | at high | +9138.4% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.77 B(+4.8%) | $10.63 B(+2.8%) |
| June 2024 | - | $2.65 B(-1.7%) | $10.34 B(+1.5%) |
| Mar 2024 | - | $2.69 B(+6.9%) | $10.19 B(+3.2%) |
| Dec 2023 | $9.87 B(+10.5%) | $2.52 B(+1.4%) | $9.87 B(+2.2%) |
| Sept 2023 | - | $2.48 B(-0.4%) | $9.65 B(+1.6%) |
| June 2023 | - | $2.49 B(+5.0%) | $9.51 B(+3.2%) |
| Mar 2023 | - | $2.37 B(+3.1%) | $9.21 B(+3.1%) |
| Dec 2022 | $8.93 B(+17.9%) | $2.30 B(-1.4%) | $8.93 B(+2.6%) |
| Sept 2022 | - | $2.33 B(+6.3%) | $8.70 B(+4.2%) |
| June 2022 | - | $2.20 B(+4.7%) | $8.35 B(+5.1%) |
| Mar 2022 | - | $2.10 B(+1.2%) | $7.95 B(+4.9%) |
| Dec 2021 | $7.57 B(+22.1%) | $2.07 B(+4.5%) | $7.57 B(+6.2%) |
| Sept 2021 | - | $1.98 B(+10.6%) | $7.13 B(+6.7%) |
| June 2021 | - | $1.79 B(+4.0%) | $6.68 B(+4.2%) |
| Mar 2021 | - | $1.72 B(+5.9%) | $6.41 B(+3.4%) |
| Dec 2020 | $6.21 B(+49.1%) | $1.63 B(+5.8%) | $6.21 B(+3.6%) |
| Sept 2020 | - | $1.54 B(+0.9%) | $5.99 B(+10.9%) |
| June 2020 | - | $1.52 B(+0.6%) | $5.40 B(+12.1%) |
| Mar 2020 | - | $1.52 B(+7.2%) | $4.82 B(+15.8%) |
| Dec 2019 | $4.16 B(+36.6%) | $1.41 B(+48.8%) | $4.16 B(+15.0%) |
| Sept 2019 | - | $949.83 M(+0.9%) | $3.62 B(+4.8%) |
| June 2019 | - | $941.29 M(+9.7%) | $3.45 B(+5.8%) |
| Mar 2019 | - | $858.43 M(-1.3%) | $3.27 B(+7.1%) |
| Dec 2018 | $3.05 B(+22.5%) | $870.11 M(+10.9%) | $3.05 B(+7.7%) |
| Sept 2018 | - | $784.53 M(+4.3%) | $2.83 B(+7.9%) |
| June 2018 | - | $752.16 M(+17.4%) | $2.62 B(+8.6%) |
| Mar 2018 | - | $640.80 M(-1.7%) | $2.41 B(-3.0%) |
| Dec 2017 | $2.49 B(+46.2%) | $651.63 M(+12.7%) | $2.49 B(+8.4%) |
| Sept 2017 | - | $578.16 M(+6.3%) | $2.30 B(+7.7%) |
| June 2017 | - | $544.13 M(-23.9%) | $2.13 B(+5.6%) |
| Mar 2017 | - | $714.72 M(+55.8%) | $2.02 B(+18.6%) |
| Dec 2016 | $1.70 B(+64.9%) | $458.71 M(+10.9%) | $1.70 B(+2.5%) |
| Sept 2016 | - | $413.78 M(-4.1%) | $1.66 B(+6.7%) |
| June 2016 | - | $431.61 M(+8.4%) | $1.56 B(+20.6%) |
| Mar 2016 | - | $398.08 M(-4.8%) | $1.29 B(+25.1%) |
| Dec 2015 | $1.03 B(+77.9%) | $417.94 M(+34.9%) | $1.03 B(+36.0%) |
| Sept 2015 | - | $309.82 M(+86.6%) | $758.96 M(+20.8%) |
| June 2015 | - | $166.08 M(+19.9%) | $628.13 M(+4.6%) |
| Mar 2015 | - | $138.51 M(-4.2%) | $600.47 M(+3.5%) |
| Dec 2014 | $580.41 M(-52.1%) | $144.56 M(-19.2%) | $580.41 M(-26.3%) |
| Sept 2014 | - | $178.99 M(+29.3%) | $787.02 M(-5.1%) |
| June 2014 | - | $138.42 M(+16.9%) | $829.73 M(-17.2%) |
| Mar 2014 | - | $118.45 M(-66.3%) | $1.00 B(-17.3%) |
| Dec 2013 | $1.21 B(-20.6%) | $351.16 M(+58.4%) | $1.21 B(+1.4%) |
| Sept 2013 | - | $221.70 M(-28.7%) | $1.19 B(-8.7%) |
| June 2013 | - | $310.75 M(-5.4%) | $1.31 B(-7.6%) |
| Mar 2013 | - | $328.37 M(-1.7%) | $1.42 B(-7.2%) |
| Dec 2012 | $1.53 B(+8.3%) | $333.99 M(-0.6%) | $1.53 B(-13.1%) |
| Sept 2012 | - | $336.01 M(-19.7%) | $1.76 B(-15.5%) |
| June 2012 | - | $418.31 M(-4.7%) | $2.08 B(+17.1%) |
| Mar 2012 | - | $438.74 M(-22.1%) | $1.78 B(+25.9%) |
| Dec 2011 | $1.41 B(+883.9%) | $563.34 M(-14.5%) | $1.41 B(+54.5%) |
| Sept 2011 | - | $659.20 M(+476.1%) | $912.81 M(+229.1%) |
| June 2011 | - | $114.42 M(+55.3%) | $277.40 M(+42.5%) |
| Mar 2011 | - | $73.66 M(+12.4%) | $194.60 M(+35.7%) |
| Dec 2010 | $143.37 M(+40.7%) | $65.52 M(+175.4%) | $143.37 M(+28.3%) |
| Sept 2010 | - | $23.80 M(-24.8%) | $111.73 M(-1.0%) |
| June 2010 | - | $31.62 M(+41.0%) | $112.90 M(+12.5%) |
| Mar 2010 | - | $22.43 M(-33.8%) | $100.34 M(-1.5%) |
| Dec 2009 | $101.89 M(-41.9%) | $33.89 M(+35.8%) | $101.89 M(+1.1%) |
| Sept 2009 | - | $24.96 M(+30.9%) | $100.81 M(-6.2%) |
| June 2009 | - | $19.06 M(-20.5%) | $107.46 M(-31.9%) |
| Mar 2009 | - | $23.98 M(-26.9%) | $157.81 M(-10.1%) |
| Dec 2008 | $175.50 M(-11.8%) | $32.81 M(+3.8%) | $175.50 M(-9.4%) |
| Sept 2008 | - | $31.61 M(-54.5%) | $193.69 M(-4.6%) |
| June 2008 | - | $69.41 M(+66.5%) | $203.09 M(+18.2%) |
| Mar 2008 | - | $41.67 M(-18.3%) | $171.88 M(-13.6%) |
| Dec 2007 | $199.01 M | $50.99 M(+24.3%) | $199.01 M(-17.9%) |
| Sept 2007 | - | $41.01 M(+7.4%) | $242.27 M(-4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | $38.20 M(-44.5%) | $254.55 M(+3.4%) |
| Mar 2007 | - | $68.81 M(-27.0%) | $246.08 M(+13.7%) |
| Dec 2006 | $216.36 M(+34.5%) | $94.25 M(+76.9%) | $216.36 M(+16.4%) |
| Sept 2006 | - | $53.29 M(+79.3%) | $185.86 M(+10.1%) |
| June 2006 | - | $29.73 M(-23.9%) | $168.78 M(-1.5%) |
| Mar 2006 | - | $39.09 M(-38.7%) | $171.37 M(+6.5%) |
| Dec 2005 | $160.89 M(+56.6%) | $63.76 M(+76.1%) | $160.89 M(+17.5%) |
| Sept 2005 | - | $36.21 M(+12.0%) | $136.97 M(+7.4%) |
| June 2005 | - | $32.32 M(+13.0%) | $127.59 M(+12.1%) |
| Mar 2005 | - | $28.61 M(-28.2%) | $113.81 M(+10.8%) |
| Dec 2004 | $102.72 M(+48.6%) | $39.84 M(+48.5%) | $102.72 M(+21.9%) |
| Sept 2004 | - | $26.83 M(+44.7%) | $84.26 M(+15.0%) |
| June 2004 | - | $18.54 M(+5.9%) | $73.25 M(+1.3%) |
| Mar 2004 | - | $17.51 M(-18.1%) | $72.29 M(-6.6%) |
| Dec 2003 | $69.14 M(-27.0%) | $21.38 M(+35.1%) | $77.39 M(+131.2%) |
| Sept 2003 | - | $15.82 M(-10.0%) | $33.48 M(-35.5%) |
| June 2003 | - | $17.58 M(-22.3%) | $51.93 M(-32.3%) |
| Mar 2003 | - | $22.61 M(-200.3%) | $76.68 M(-19.1%) |
| Dec 2002 | $94.77 M(+11.1%) | -$22.53 M(-165.7%) | $94.77 M(+9.4%) |
| Sept 2002 | - | $34.28 M(-19.0%) | $86.63 M(-6.6%) |
| June 2002 | - | $42.33 M(+4.0%) | $92.72 M(+29.1%) |
| Mar 2002 | - | $40.70 M(-232.7%) | $71.84 M(+43.1%) |
| Dec 2001 | $85.30 M(-44.4%) | -$30.67 M(-176.0%) | $50.20 M(-71.4%) |
| Sept 2001 | - | $40.37 M(+88.3%) | $175.73 M(+17.8%) |
| June 2001 | - | $21.44 M(+12.5%) | $149.22 M(-9.5%) |
| Mar 2001 | - | $19.06 M(-79.9%) | $164.82 M(+7.1%) |
| Dec 2000 | $153.28 M(+202.9%) | $94.86 M(+584.1%) | $153.89 M(+79.1%) |
| Sept 2000 | - | $13.87 M(-62.6%) | $85.93 M(+8.4%) |
| June 2000 | - | $37.03 M(+355.4%) | $79.26 M(+44.8%) |
| Mar 2000 | - | $8.13 M(-69.8%) | $54.74 M(+8.2%) |
| Dec 1999 | $50.60 M(+73.9%) | $26.90 M(+273.6%) | $50.61 M(+151.6%) |
| Sept 1999 | - | $7.20 M(-42.5%) | $20.12 M(-35.8%) |
| June 1999 | - | $12.52 M(+212.9%) | $31.32 M(+20.4%) |
| Mar 1999 | - | $4.00 M(-211.1%) | $26.00 M(+3.2%) |
| Dec 1998 | $29.10 M(-33.6%) | -$3.60 M(-119.6%) | $25.20 M(-37.0%) |
| Sept 1998 | - | $18.40 M(+155.6%) | $40.00 M(+14.0%) |
| June 1998 | - | $7.20 M(+125.0%) | $35.10 M(-12.5%) |
| Mar 1998 | - | $3.20 M(-71.4%) | $40.10 M(-8.4%) |
| Dec 1997 | $43.80 M(+135.5%) | $11.20 M(-17.0%) | $43.80 M(+2.6%) |
| Sept 1997 | - | $13.50 M(+10.7%) | $42.70 M(+33.0%) |
| June 1997 | - | $12.20 M(+76.8%) | $32.10 M(+39.6%) |
| Mar 1997 | - | $6.90 M(-31.7%) | $23.00 M(+23.7%) |
| Dec 1996 | $18.60 M(-15.8%) | $10.10 M(+248.3%) | $18.60 M(+11.4%) |
| Sept 1996 | - | $2.90 M(-6.5%) | $16.70 M(+3.7%) |
| June 1996 | - | $3.10 M(+24.0%) | $16.10 M(-17.4%) |
| Mar 1996 | - | $2.50 M(-69.5%) | $19.50 M(-11.8%) |
| Dec 1995 | $22.10 M(+12.8%) | $8.20 M(+256.5%) | $22.10 M(+33.1%) |
| Sept 1995 | - | $2.30 M(-64.6%) | $16.60 M(-20.2%) |
| June 1995 | - | $6.50 M(+27.5%) | $20.80 M(+8.9%) |
| Mar 1995 | - | $5.10 M(+88.9%) | $19.10 M(-2.6%) |
| Dec 1994 | $19.60 M(-29.7%) | $2.70 M(-58.5%) | $19.60 M(-43.8%) |
| Sept 1994 | - | $6.50 M(+35.4%) | $34.90 M(+6.4%) |
| June 1994 | - | $4.80 M(-14.3%) | $32.80 M(+0.6%) |
| Mar 1994 | - | $5.60 M(-68.9%) | $32.60 M(+16.8%) |
| Dec 1993 | $27.90 M(+634.2%) | $18.00 M(+309.1%) | $27.90 M(+156.0%) |
| Sept 1993 | - | $4.40 M(-4.3%) | $10.90 M(+45.3%) |
| June 1993 | - | $4.60 M(+411.1%) | $7.50 M(+92.3%) |
| Mar 1993 | - | $900.00 K(-10.0%) | $3.90 M(0.0%) |
| Dec 1992 | $3.80 M(+18.8%) | $1.00 M(0.0%) | $3.90 M(+5.4%) |
| Sept 1992 | - | $1.00 M(0.0%) | $3.70 M(+5.7%) |
| June 1992 | - | $1.00 M(+11.1%) | $3.50 M(+6.1%) |
| Mar 1992 | - | $900.00 K(+12.5%) | $3.30 M(+3.1%) |
| Dec 1991 | $3.20 M(+39.1%) | $800.00 K(0.0%) | $3.20 M(+6.7%) |
| Sept 1991 | - | $800.00 K(0.0%) | $3.00 M(+7.1%) |
| June 1991 | - | $800.00 K(0.0%) | $2.80 M(+7.7%) |
| Mar 1991 | - | $800.00 K(+33.3%) | $2.60 M(+13.0%) |
| Dec 1990 | $2.30 M | $600.00 K(0.0%) | $2.30 M(+35.3%) |
| Sept 1990 | - | $600.00 K(0.0%) | $1.70 M(+54.5%) |
| June 1990 | - | $600.00 K(+20.0%) | $1.10 M(+120.0%) |
| Mar 1990 | - | $500.00 K | $500.00 K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual revenue?
- What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly revenue?
- What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM revenue?
- What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual revenue?
The current annual revenue of VRTX is $9.87 B
What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual revenue is $9.87 B
What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?
Over the past year, VRTX annual revenue has changed by +$938.50 M (+10.51%)
What is Vertex Pharmaceuticals Incorporated quarterly revenue?
The current quarterly revenue of VRTX is $2.77 B
What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly revenue is $2.77 B
What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?
Over the past year, VRTX quarterly revenue has changed by +$288.40 M (+11.61%)
What is Vertex Pharmaceuticals Incorporated TTM revenue?
The current TTM revenue of VRTX is $10.63 B
What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM revenue is $10.63 B
What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?
Over the past year, VRTX TTM revenue has changed by +$971.60 M (+10.06%)